Episode 15: The Latest Developments in the SMA Treatment Landscape

August 14, 2020
Matt Hoffman
Matt Hoffman

Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017, and previously wrote for its sister publication, HCPLive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Richard Finkel, MD.

Richard Finkel, MD

Episode 15 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 15, "A New Approval: The SMA Treatment Landscape," features an interview with Richard Finkel, MD, pediatric neurologist, and head, Center for Experimental Neurotherapeutics, St. Jude Children’s Research Hospital. Finkel offered an in-depth look at how the recent FDA approval of oral risdiplam (Evrysdi; Roche) might impact the spinal muscular atrophy (SMA) therapeutic landscape.

Click here to subscribe to the Mind Moments podcast. Thanks for listening!

Related Content:

Clinical | News | Neuromuscular